Results 371 to 380 of about 456,743 (411)

Angiotensin-Converting Enzyme Inhibitors

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2014
Angiotensin-converting enzyme inhibitors (ACEIs) can be classified into two sub groups according to their chemical structure: the one containing a thiol (or sulfhydryl [SH]) group such as captopril and zofenopril, and the other lacking a thiol group such as enalapril, ramipril, cilazapril, fosinopril, quinapril, trandolapril, lisinopril, perindopril ...
Kurtuluş Didem Yazganoğlu, Esen Özkaya   +1 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Angiotensin-Converting Enzyme Inhibitors

Journal of Hypertension, 1991
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr,
Irene Gavras, Haralambos Gavras
openaire   +5 more sources

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1988
There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure.
Roger K. Ferguson, Peter H. Vlasses, Heschi H. Rotmensch   +2 more
  +8 more sources

A radioassay for angiotensin converting enzyme

Clinical Biochemistry, 1984
Current methods for measuring angiotensin converting enzyme activity (EC 3.4.15.1, ACE) are somewhat cumbersome and have limited the general availability of the test. We describe here a simple four-step radioassay for ACE which uses the substrate 14C-Hippurate-L-Histidyl-L-Leucine and measures the product, 14C-Hippurate.
Martha Sample, Tjien O. Oei, Daniel C. Smith, Richard B. Sample, Kenneth W. Ryder, Hannis Thompson   +5 more
openaire   +3 more sources

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

New England Journal of Medicine, 2000
BACKGROUND Angiotensin-converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure.
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais   +5 more
semanticscholar   +1 more source

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Journal of the American Medical Association (JAMA), 2002
CONTEXT Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. K. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara M. Simpson, J. Blanton, T. Geraci, Sandra M. Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Ann Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. L. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi   +56 more
semanticscholar   +1 more source

Angiotensin-Converting Enzyme in Neurosarcoidosis

Archives of Neurology, 1987
To the Editor. —We read with great interest the article by Sethi et al in the June 1986 issue of theArchives.1We wish to point out another important aspect of neurosarcoidosis that was not discussed by the authors, namely, determination of angiotensin I—converting enzyme (ACE) levels in the cerebrospinal fluid (CSF) of patients with suspected ...
Israel Rubinstein, Victor Hoffstein
openaire   +3 more sources

Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review

Expert Review of Clinical Pharmacology, 2022
Angiotensin converting enzyme inhibitors (ACEI) are commonly used for cardiovascular diseases. The evidence supporting the use of ACEI in dermatology is limited.This review article was divided into three parts. The first part discusses ACEI in clinical use in dermatology.
Yang, Lo, Tsen-Fang, Tsai
openaire   +2 more sources

The angiotensin converting enzyme in the kidney

Journal of Hypertension, 1989
Immunohistochemical studies and experiments with microdissected nephron segments indicate that the angiotensin I converting enzyme (ACE) in the kidney is expressed in the vascular endothelial cells of the renal vessels and in the epithelial cells of the proximal convoluted tubule and the pars recta.
Florent Soubrier, T. Baussant, Christine Hubert, François Alhenc-Gelas, Pierre Corvol   +4 more
openaire   +3 more sources

Angiotensin-converting enzyme inhibitors

Critical Care Nurse, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
BL Herlihy, JT Herlihy
openaire   +5 more sources